Algorae Pharmaceuticals Limited (LVCLF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $14.5M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAlgorae Pharmaceuticals Limited (LVCLF) trades at $0.00716. Algorae Pharmaceuticals Limited (LVCLF) is a biotechnology company focused on developing innovative therapies for neurological and cardiovascular diseases. Market cap: $14.5M, Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for LVCLF: LVCLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Algorae Pharmaceuticals Limited (LVCLF) Healthcare & Pipeline Overview
Algorae Pharmaceuticals Limited specializes in developing advanced therapeutics for serious health conditions, including dementia and Parkinson's disease, with a focus on innovative living cell technologies and artificial intelligence-driven drug development.
What Is the Investment Thesis for LVCLF?
Algorae Pharmaceuticals Limited presents a compelling case for growth within the biotechnology sector, driven by its innovative product pipeline and strategic partnerships. The company’s market capitalization stands at approximately $14.39 million, reflecting its potential for expansion as it advances its clinical candidates. Key value drivers include the ongoing development of AI-116, NTCELL, and AI-168, which target significant health issues like dementia and Parkinson's disease, expected to see increased demand due to aging populations. The partnership with the University of New South Wales for AlgaraeOS enhances the company's capability to innovate in drug development, potentially positioning it ahead of competitors. However, risks include the inherent volatility of OTC trading, limited liquidity, and the challenges associated with regulatory approvals for its drug candidates. Investors should monitor clinical trial results and regulatory milestones closely, as these will be crucial in determining the company's future trajectory.
Based on FMP financials and quantitative analysis
LVCLF Key Highlights
Market capitalization of approximately $14.39 million, indicating a small-cap status with potential for growth.
- Focus on innovative therapies targeting high-prevalence conditions such as dementia and Parkinson's disease.
- Strong collaboration with the University of New South Wales to develop AI-driven drug prediction technology.
- No dividend yield, reflecting a reinvestment strategy typical for early-stage biotechnology firms.
- Beta of -0.08, suggesting lower volatility compared to the broader market.
Who Are LVCLF's Competitors?
LVCLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc. | $15.13 | -1.75% | $2.03B | 97 5-pillar |
| NVAX Novavax, Inc. | $7.72 | -3.02% | $1.27B | — |
| PFE Pfizer Inc. | $28.06 | -1.44% | $160B | 67 5-pillar |
| BMY Bristol-Myers Squibb Company | $58.34 | -2.05% | $119B | 85 5-pillar |
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LVCLF's Key Strengths?
Innovative product pipeline targeting significant health issues.
- Strong partnerships enhancing research capabilities.
- Experienced management team with industry expertise.
- Proprietary technologies that differentiate offerings.
What Are LVCLF's Weaknesses?
Limited market presence compared to larger competitors.
- Dependence on successful clinical trial outcomes.
- No current revenue streams due to the early-stage nature of products.
- Higher volatility associated with OTC trading.
What Are the Key Risks for LVCLF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What Threats Does LVCLF Face?
- Intense competition from established biotech firms.
- Regulatory challenges in drug approval processes.
- Market volatility affecting investor sentiment.
- Potential for patent expirations impacting product exclusivity.
What Are LVCLF's Competitive Advantages?
- Strong focus on innovative therapies that address high-prevalence diseases.
- Proprietary living cell technologies that differentiate product offerings.
- Strategic partnerships with academic institutions for advanced research.
- A unique AI-driven platform for predicting drug targets, enhancing R&D efficiency.
- A dedicated team with expertise in biotechnology and pharmaceutical development.
What Does LVCLF Do?
Founded in 1987, Algorae Pharmaceuticals Limited is a Melbourne-based pharmaceutical development company that has evolved significantly over the years. Originally operating under the name Living Cell Technologies Limited, the company rebranded to Algorae Pharmaceuticals Limited in September 2023 to better reflect its focus on innovative therapeutic solutions. Algorae conducts its research and development primarily in New Zealand, where it leverages advanced living cell technologies to create groundbreaking treatments. The company’s product pipeline includes several promising candidates: AI-116, a novel combination therapy that pairs cannabidiol with an existing pharmaceutical ingredient to target dementia and Alzheimer's disease; NTCELL, an alginate-coated capsule designed to address Parkinson's disease; and AI-168, another combination drug that merges a cannabinoid with an off-patent pharmaceutical ingredient aimed at treating cardiovascular conditions such as hypertension. In collaboration with the University of New South Wales, Algorae is also developing AlgaraeOS, a cutting-edge artificial intelligence platform intended to predict biopharmaceutical drug targets. This innovative approach allows for the exploration of both fixed-dose combinations and repurposed drugs without being limited by specific medical indications. With a dedicated workforce of 48 employees, Algorae Pharmaceuticals is committed to advancing healthcare through its unique and targeted drug development initiatives.
What Products and Services Does LVCLF Offer?
- Develop innovative therapies targeting neurological and cardiovascular diseases.
- Conduct research and development primarily in New Zealand.
- Utilize living cell technologies to create advanced pharmaceutical solutions.
- Collaborate with academic institutions for cutting-edge research.
- Focus on combination therapies to enhance treatment efficacy.
- Leverage artificial intelligence for drug target prediction.
How Does LVCLF Make Money?
- Generate revenue through the development and commercialization of pharmaceutical products.
- Engage in partnerships and collaborations to enhance research capabilities.
- Focus on clinical trials to advance product candidates toward regulatory approval.
- Explore licensing agreements for successful drug candidates.
- Invest in R&D to expand the product pipeline and address unmet medical needs.
What Industry Does LVCLF Operate In?
The biotechnology industry is experiencing significant growth, driven by advancements in technology and increasing demand for innovative therapies. The global biotechnology market is expected to reach $2.4 trillion by 2028, with a CAGR of over 7%. Algorae Pharmaceuticals Limited operates within this dynamic landscape, focusing on unmet medical needs in neurology and cardiology. The competitive landscape includes established players and emerging biotech firms, with a growing emphasis on personalized medicine and AI-driven drug development, positioning Algorae favorably as it leverages its unique technologies.
Who Are LVCLF's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from neurological and cardiovascular diseases.
- Pharmaceutical partners interested in collaboration and licensing.
- Research institutions engaged in biopharmaceutical development.
- Investors looking for opportunities in the biotechnology sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
How Algorae Pharmaceuticals Limited Is Valued
Algorae Pharmaceuticals Limited carries a market capitalization of $14.5M, placing it in the micro-cap category.
Company Profile
Algorae Pharmaceuticals Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, Australia.
Key Financial Metrics
Return on assets is -91.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 25.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Algorae Pharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 46.05 places it in the safe zone, indicating low near-term bankruptcy risk.
LVCLF Latest News
No recent news available for LVCLF.
LVCLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LVCLF.
Price Targets
Wall Street price target analysis for LVCLF.
LVCLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LVCLF; grades run from A+ (80-100) to F (below 30).
LVCLF OTC Market Information
LVCLF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.